Showing 4821-4830 of 8848 results for "".
- Scleroderma Treatment Breakthrough? New Study Hints At Way To Slow Skin Fibrosishttps://practicaldermatology.com/news/scleroderma-treatment-breakthrough-new-study-suggests-way-to-slow-skin-fibrosis/2458387/New and ongoing research at Hospital for Special Surgery (HSS) in New York City has identified a possible mechanism behind the fibrosis that occurs in scleroderma – a mechanism that may one day lead to a treatment for the disease. The findings appear in the
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device B
- Dr. Ken Washenik Named New President of International Society of Hair Restoration Surgeryhttps://practicaldermatology.com/news/dr-ken-washenik-named-new-president-of-international-society-of-hair-restoration-surgery/2458394/The International Society of Hair Restoration Surgery (ISHRS), a global non-profit medical association and a leading authority on hair loss treatment and restoration, elected Ken Washenik, MD, PhD, FISHRS, as President. The announcement took place at the ISHRS 24th</
- Doctors Welcome VOLBELLA XC for Lipshttps://practicaldermatology.com/news/doctors-welcome-volbella-xc-for-lips/2458401/Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21. Physicians can purchase VOLBELLA XC after completion of an
- FDA Clears Merz Aesthetics' Cellfina System for Long-Term Improvement of Cellulitehttps://practicaldermatology.com/news/fda-clears-merz-aesthetics-cellfina-system-for-long-term-improvement-of-cellulite/2458399/The FDA has cleared the Cellfina System from Merz Aesthetics, a division of Merz North America, for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years. Cellfina is the only FDA-cleared minimally in
- Vaseline Initiative Aims to Close Skin Heath Treatment Gaphttps://practicaldermatology.com/news/vaseline-initiative-aims-to-close-skin-heath-treatment-gap/2458405/The Vaseline® Healing Project in partnership with non-profit Direct Relief is working to close the skin health treatment gap for Americans by providing skin care and training along with Vaseline® products and medical supplies for those with limited access.<
- Opdivo Stabilized Patient-reported Outcomes in Previously Treated Recurrent or Metastatic SCC of Head and Neckhttps://practicaldermatology.com/news/opdivo-stabilized-patient-reported-outcomes-in-previously-treated-recurrent-or-metastatic-scc-of-head-and-neck/2458409/Bristol-Myers Squibb Company reported new patient-reported quality-of-life data from an exploratory endpoint in the pivotal Phase 3 CheckMate -141 trial evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after platinum therapy compared to inves
- At-Home Nail Fungus Treatment Now Available From iSkinProductshttps://practicaldermatology.com/news/at-home-nail-fungus-treatment-now-available-from-iskinproducts/2458415/Cure-Ex nail fungus laser treatment device is now available from online beauty retailer, iSkinProducts. The portable device can be used on fingernails or toenails and a user can use the Cure-Ex laser from the comfort of their own home, according to the company. The Cure-Ex nail fungus tre
- New From Neocutis: Meet the Micro-Riche Linehttps://practicaldermatology.com/news/new-from-neocutis-meet-the-micro-riche-line/2458420/NEOCUTIS is rolling out a new line. The MICRO-RICHE ultra-hydrating line will expand the company’s MICRO-PROTEIN Complex (MPC) product line. The new MICRO-RICHE line includes more emollient versions of MICRO-NIGHT and MICRO-EYE to keep skin nourished and hydrated as winter approache
- Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDAhttps://practicaldermatology.com/news/regeneron-and-sanofis-dupilumab-biologics-license-application-accepted-for-priority-review-by-fda/2458423/The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD). The application has been given a Prescription